{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T07:56:15Z","timestamp":1775980575213,"version":"3.50.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Yutao Wang, China Medical University, ChinaThe tumor microenvironment (TME) has been shown to impact the prognosis of tumors in patients including cutaneous melanoma (CM); however, not all components of TME are important. Given the aforementioned situation, the functional immune cell contents correlated with CM patient prognosis are needed to optimize present predictive models and reflect the overall situation of TME. We developed a novel risk score named core tumor-infiltrating immune cell score (cTICscore), which showed certain advantages over existing biomarkers or TME-related signatures in predicting the prognosis of CM patients. Furthermore, we explored a new gene signature named cTILscore\u2212related module gene score (cTMGs), based on four identified TME-associated genes (<jats:italic>GCH1<\/jats:italic>, <jats:italic>GZMA<\/jats:italic>, <jats:italic>PSMB8<\/jats:italic>, and <jats:italic>PLAAT4<\/jats:italic>) showing a close correlation with the cTICscore, which was generated by weighted gene co-expression network analysis and least absolute shrinkage and selection operator analysis to facilitate clinical application. Patients with low cTMGs had significantly better overall survival (OS, <jats:italic>P<\/jats:italic> = 0.002,&amp;lt; 0.001, = 0.002, and = 0.03, respectively) in the training and validating CM datasets. In addition, the area under the curve values used to predict the immune response in four CM cohorts were 0.723, 0.723, 0.754, and 0.792, respectively, and that in one gastric cohort was 0.764. Therefore, the four-gene signature, based on cTICscore, might improve prognostic information, serving as a predictive tool for CM patients receiving immunotherapy.cutaneous melanoma, tumor microenvironment, prognosis, immunotherapy, cTICscore<\/jats:p>","DOI":"10.3389\/fimmu.2022.914612","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T05:42:35Z","timestamp":1661146955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Zheng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zewen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanmin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01490-x","article-title":"Transcriptional regulators and alterations that drive melanoma initiation and progression","volume":"39","author":"Gupta","year":"2020","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12967-021-03002-1","article-title":"Immune and stromal scoring system associated with tumor microenvironment and prognosis: A gene-based multi-cancer analysis","volume":"19","author":"Zeng","year":"2021","journal-title":"J Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1543","article-title":"Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma","volume":"22","author":"Vassilakopoulou","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622563","article-title":"9-gene signature correlated with CD8(+) T cell infiltration activated by IFN-\u03b3: A biomarker of immune checkpoint therapy response in melanoma","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659444","article-title":"Development and validation of a CD8+ T cell infiltration-related signature for melanoma patients","volume":"12","author":"Yuan","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3762","article-title":"Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy","volume":"31","author":"Ulloa-Montoya","year":"2013","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3655","article-title":"Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy","volume":"6","author":"Cirenajwis","year":"2015","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"Jonsson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29047","article-title":"Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information","volume":"136","author":"Jayawardana","year":"2015","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41525-021-00169-w","article-title":"Ratio of the interferon-\u03b3 signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma","volume":"6","author":"Cui","year":"2021","journal-title":"NPJ Genom Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13073-021-00885-z","article-title":"Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis","volume":"13","author":"Wu","year":"2021","journal-title":"Genome Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/1878-0261.12639","article-title":"Metabolism-associated molecular classification of hepatocellular carcinoma","volume":"14","author":"Yang","year":"2020","journal-title":"Mol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00374","article-title":"Prognostic genes of breast cancer identified by gene Co-expression network analysis","volume":"8","author":"Tang","year":"2018","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12747","article-title":"Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer","volume":"14","author":"Zheng","year":"2020","journal-title":"Mol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612784","article-title":"Integrated analysis of the ETS family in melanoma reveals a regulatory role of ETV7 in the immune microenvironment","volume":"11","author":"Qu","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.596679","article-title":"Development and validation of a combined ferroptosis and immune prognostic classifier for hepatocellular carcinoma","volume":"8","author":"Liu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients","volume":"7","author":"Cursons","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.573141","article-title":"Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma","volume":"10","author":"Kang","year":"2020","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.03.020","article-title":"Prognostic and clinicopathological value of PD-L1 in melanoma: A meta-analysis","volume":"359","author":"Xu","year":"2020","journal-title":"Am J Med Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"106821","DOI":"10.1016\/j.intimp.2020.106821","article-title":"A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma","volume":"87","author":"Tian","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3438","article-title":"Development of an IFNgamma response-related signature for predicting the survival of cutaneous melanoma","volume":"9","author":"Hu","year":"2020","journal-title":"Cancer Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0701-2","article-title":"The metabolite BH4 controls T cell proliferation in autoimmunity and cancer","volume":"563","author":"Cronin","year":"2018","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7548","article-title":"Granzyme a from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells","volume":"368","author":"Zhou","year":"2020","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-020-14639-9","article-title":"Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma","volume":"11","author":"Kalaora","year":"2020","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.06.012","article-title":"Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity","volume":"124","author":"Barral","year":"2009","journal-title":"Pharmacol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.015","article-title":"Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3","volume":"67","author":"Wei","year":"2017","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/gr.273300.120","article-title":"A single-cell tumor immune atlas for precision oncology","volume":"31","author":"Nieto","year":"2021","journal-title":"Genome Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"107940","DOI":"10.1016\/j.intimp.2021.107940","article-title":"A stromal and immune cell infiltration-based score model predicts prognosis and chemotherapy effect in colorectal cancer","volume":"99","author":"Luo","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B49","article-title":"Genetic variants of EML1 and HIST1H4E in myeloid cell-related pathway genes independently predict cutaneous melanoma-specific survival","volume":"11","author":"He","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"119307","DOI":"10.1016\/j.lfs.2021.119307","article-title":"A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets","volume":"273","author":"Yang","year":"2021","journal-title":"Life Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.674863","article-title":"CCDC137 is a prognostic biomarker and correlates with immunosuppressive tumor microenvironment based on pan-cancer analysis","volume":"8","author":"Guo","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/icb.2016.14","article-title":"Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen","volume":"94","author":"Shklovskaya","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.immuni.2007.04.010","article-title":"Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme b and perforin mRNAs","volume":"26","author":"Fehniger","year":"2007","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s40425-019-0697-7","article-title":"Natural killer T cell activation increases iNOS(+)CD206(-) M1 macrophage and controls the growth of solid tumor","volume":"7","author":"Paul","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.3390\/molecules25204831","article-title":"Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy","volume":"25","author":"Li","year":"2020","journal-title":"Molecules"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2021.04.013","article-title":"Lipid metabolism in cancer: New perspectives and emerging mechanisms","volume":"56","author":"Broadfield","year":"2021","journal-title":"Dev Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): In silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research TMB harmonization project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"Elife"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.028","article-title":"Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment","volume":"30","author":"Han","year":"2022","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.914612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T05:42:40Z","timestamp":1661146960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.914612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2022.914612"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.914612","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"914612"}}